Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
84.3 EUR | +1.93% | +6.10% | +40.03% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.03% | 4.67B | |
+34.00% | 704B | |
+26.93% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.08% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi Denies Receiving Unlawful Public Grants